These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1233 related articles for article (PubMed ID: 31478503)

  • 1. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates as Cancer Therapeutics: Past, Present, and Future.
    Vezina HE; Cotreau M; Han TH; Gupta M
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S11-S25. PubMed ID: 28921650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates.
    Kamath AV; Iyer S
    Pharm Res; 2015 Nov; 32(11):3470-9. PubMed ID: 25446773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy.
    Nakada T; Sugihara K; Jikoh T; Abe Y; Agatsuma T
    Chem Pharm Bull (Tokyo); 2019; 67(3):173-185. PubMed ID: 30827997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugate-Based Therapeutics: State of the Science.
    Birrer MJ; Moore KN; Betella I; Bates RC
    J Natl Cancer Inst; 2019 Jun; 111(6):538-549. PubMed ID: 30859213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
    Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
    Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
    Burke JM; Morschhauser F; Andorsky D; Lee C; Sharman JP
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1073-1083. PubMed ID: 32985934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
    Tsuchikama K; An Z
    Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the choice of monoclonal antibodies for antibody-drug conjugates.
    Hasan MM; Laws M; Jin P; Rahman KM
    Drug Discov Today; 2022 Jan; 27(1):354-361. PubMed ID: 34597756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugates: Principles and opportunities.
    Phuna ZX; Kumar PA; Haroun E; Dutta D; Lim SH
    Life Sci; 2024 Jun; 347():122676. PubMed ID: 38688384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
    Leal AD; Krishnamurthy A; Head L; Messersmith WA
    Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
    Liu SN; Li C
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates for Breast Cancer.
    Marmé F
    Oncol Res Treat; 2022; 45(1-2):26-36. PubMed ID: 34915488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The target invites a foe: antibody-drug conjugates in gynecologic oncology.
    Campos MP; Konecny GE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):44-50. PubMed ID: 29227302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and challenges of antibody drug conjugates as novel form of chemotherapy.
    Fatima SW; Khare SK
    J Control Release; 2022 Jan; 341():555-565. PubMed ID: 34906604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unlocking the potential of antibody-drug conjugates for cancer therapy.
    Drago JZ; Modi S; Chandarlapaty S
    Nat Rev Clin Oncol; 2021 Jun; 18(6):327-344. PubMed ID: 33558752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody drug conjugates as targeted cancer therapy: past development, present challenges and future opportunities.
    Maiti R; Patel B; Patel N; Patel M; Patel A; Dhanesha N
    Arch Pharm Res; 2023 May; 46(5):361-388. PubMed ID: 37071273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody-Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation.
    Bai C; Reid EE; Wilhelm A; Shizuka M; Maloney EK; Laleau R; Harvey L; Archer KE; Vitharana D; Adams S; Kovtun Y; Miller ML; Chari R; Keating TA; Yoder NC
    Bioconjug Chem; 2020 Jan; 31(1):93-103. PubMed ID: 31747250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.